NCT06608355招募中1 期
A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of NouvNeu001 Injection in the Treatment of Early-onset Parkinson's Disease
iRegene Therapeutics Co., Ltd.1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2024年8月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Safety and Tolerability
研究概览
简要总结
The goal of this clinical trial is to learn about the safety of NouvNeu001 injection in Early-onset Parkinson's Disease (EOPD) patients. It will also learn about the effects of NouvNeu001 treatment. The main questions it aims to answer are:
What medical problems do participants have when transplanting NouvNeu001 into bilateral putamen using stereotactic neurosurgery? Does injection of NouvNeu001 improve the motor function and non-motor function in participants?
Participants will:
Be injectioned the NouvNeu001 into bilateral putamen using stereotactic neurosurgery.
Take immunosuppressants to prevent potential immune rejection for 24 to 36 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-70 years old, male or female
- •Able to understand the rationale of the clinical trial and sign informed consent form (ICF)
- •Diagnosis of Early-onset Parkinson's Disease in accordance with the MDS clinical diagnostic criteria for Parkinson's disease, and the age of onset was ≤50 years old
- •Medically suitable for neurosurgery under anesthesia and able to participate in Computed Tomography (CT)/Magnetic Resonance Imaging (MRI) scan.
- •Hoehn-Yahr staging for "off" episodes is 2 to 4
- •The MDS-UPDRS-III score in the "off" state >30, and positive for the Acute Levodopa Challenge Test (ALCT)
- •Acceptable laboratory test results during screening and prior to transplantation
排除标准
- •Atypical Parkinsonism
- •Patients who have had previous pallidotomy, striatal or extrapyramidal surgery or other brain surgery; as well as other surgical procedures that are judged by the investigator to affect patient's participation in this study; Patients with surgical contraindications or other neurosurgical contraindications
- •Patients who have a previous head CT/MRI examination showing cerebral trauma, vascular malformation, hydrocephalus, brain tumor, etc., and patients who have brain imaging abnormalities in the striatum or other brain areas leading to a significantly increased risk for surgery
- •Patients with a history of severe cardiovascular and cerebrovascular diseases
- •Patients with a history of malignant tumors
- •Patients who have received stem cell therapy for Parkinson's disease within 2 years before signing the ICF
- •Patients with active disseminated intravascular coagulation and significant hemorrhagic tendency within 3 months prior to screening, or who cannot temporarily suspend anti-platelet agents or other anti-coagulant medications for at least 5 days before surgery
- •Patients with long-term, heavy use of glucocorticoids or immunosuppressive drugs within 3 months prior to signing the ICF
- •Patients with a history of mental illness who are deemed unfit to participate in the study by the investigator; or a history of suicidal ideation or suicide attempts within the past year or currently
- •Patients who have used botulinum toxin within 6 months prior to signing the ICF
- •Patients with active epilepsy or currently on anti-epileptic drugs
- •Patients with a history of dementia or severe cognitive disorder, or the score of MDS-UPDRS 1.1 during screening is > 3; poor compliance, inability to accurately keep diary, and/or inability to sign ICF due to dementia
- •Patients with severe depression or with severe anxiety
- •Patients with the following abnormalities during screening, including: Abnormal coagulation; Abnormal immunological tests, and assessed by the investigator it is not suitable to participate in the trial; Hypertensive patients with poorly controlled blood pressure and patients with severe postural hypotension; Diabetic patients with poorly controlled blood glucose
- •Patients with other combined severe systemic diseases, such as pulmonary heart disease, moderate to severe asthma, severe chronic obstructive pulmonary disease (COPD)
- •Presence of one of the following: positive for human immunodeficiency virus (HIV) antibody, treponema pallidum antibody, hepatitis C virus (HCV) antibody and HCV RNA; Hepatitis B virus (HBV) surface antigen positive and HBV DNA copy number > detection of normal values; Tuberculosis is in the active stage; Other active infections that the investigator believes may affect Patients' participation in the study or affect study outcomes
- •Patients with alcohol addiction or positive for drug of abuse testing
- •Patients with a history of contraindication or allergy to the drugs used during the study or any of its components, or are allergic to the same drugs or other macrolides, or have allergies
- •Female of childbearing potential who are not surgically sterilized/premenopausal/unwilling to use medically approved effective contraception with 2 years after administration of investigational drug and lactating women; men who are not surgically sterilized/unwilling to use medically approved effective contraception with 2 years after administration of investigational drug
- •Patients who have received electric shock therapy within 30 days prior to surgery
- •Patients who are participating in other clinical trials, or have been enrolled in other clinical studies and received intervention therapy within 3 months prior to the surgery
- •Patients with poor compliance based on clinical evaluation of the investigator
- •Patients who are being treated with drugs such as apomorphine, or levodopa/carbidopa infusion therapy
- •Patients with severe dyskinesia in both on- and off-drug states
研究组 & 干预措施
NouvNeu001
Experimental
干预措施: Human Dopaminergic Progenitor Cells (Biological)
结局指标
主要结局
Safety and Tolerability
时间窗: Enrollment to 96 weeks post-transplant.
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
次要结局
- The Motor Function and Non-motor Function(Baseline to 48 weeks and 96 weeks post-transplant)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
BC008-1A Injection for Recurrent CNS WHO G4 GliomaGlioma Tumor RecurrenceGlioma, Recurrent High GradeGlioblastomas (GBM)Glioblastoma WHO Grade IVGliomaNCT06773481Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.40
进行中（未招募）
1 期
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)Hematological MalignanciesNCT05347225Merck Sharp & Dohme LLC12
尚未招募
1 期
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid TumorAdvanced Malignant Solid TumorNCT06166472Akeso72
已完成
不适用
Phase I clinical study to evaluate the safety and tolerability of Quadrivalent Influenza Vaccine (QIV) delivered intradermally by a high-density micro-array patch (HD MAP), compared to intramuscular Influvac® Tetra injection, in healthy adults aged 18 to 50 yearsrespiratory infectionRespiratory - Other respiratory disorders / diseasesInfluenzaACTRN12622001203741Vaxxas Pty Ltd150
已完成
不适用
Phase I clinical study to evaluate the safety and tolerability of SARS-CoV-2 spike protein (HexaPro) delivered intradermally by a high-density microarray patch (HD-MAP), in healthy adults aged 18 to 50 years.SARS-CoV-2 infectionInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12622000597796Vaxxas Pty Ltd44